ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma

This article was originally published here

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) target date of May 21, 2021. “The FDA’s acceptance of our BLA and granting of priority review

The post ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply